Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.
Yolanda Braun-MoscoviciMarielle KaplanMaya BraunDoron MarkovitsSamy GiryesKohava ToledanoYonit TavorKatya DolnikovAlexandra Balbir-GurmanPublished in: Annals of the rheumatic diseases (2021)
The vast majority of patients with IRD developed a significant humoral response following the administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2 virus. Only minor side effects were reported and no apparent impact on IRD activity was noted.